AbCellera Biologics Inc. (ABCL) Sentiment Analysis
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
- ST sentiment gradeHow the market currently feels about this stock versus its peers
- —
- Overall ST grade
- B-
- ST Score
- 53.2
- Price change today
- —
- Strong buy
- —
- Buy
- —
- Hold
- —
- Sell
- —
- Strong sell
- —
- Bullish share0 bullish vs 0 bearish ratings
- —
Headline tone is a simple keyword scan of recent coverage, not a prediction.
ABCL stock: frequently asked questions
What is ABCL's ST Score?
AbCellera Biologics Inc. (ABCL) has an ST Score of 53.2 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is ABCL a buy, hold, or sell?
Analysts rate ABCL a Buy, with a price target of $14.75 (+16.6% vs the current price). Our ST Score grades it B- (53.2/100). The ST Score is a data-driven signal, not a recommendation.
What are ABCL's factor grades?
Valuation C, Profitability A-, Financial Strength B, Momentum A-, Growth F, Forecast B+.
What is ABCL's valuation grade?
AbCellera Biologics Inc. (ABCL) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is ABCL's growth grade?
AbCellera Biologics Inc. (ABCL) earns a growth grade of F, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is ABCL's profitability grade?
AbCellera Biologics Inc. (ABCL) earns a profitability grade of A-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is ABCL's financial strength grade?
AbCellera Biologics Inc. (ABCL) earns a financial strength grade of B, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for ABCL?
The average analyst price target for AbCellera Biologics Inc. (ABCL) is $14.75 from 12 analysts, which is +16.6% versus the recent price of $12.65.
What is ABCL's Piotroski score?
AbCellera Biologics Inc. (ABCL) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.